Ferritin Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The ferritin testing market size was valued at USD 0.977 billion in 2025 and estimated to grow from USD 1.03 billion in 2026 to reach USD 1.37 billion by 2031, at a CAGR of 5.78% during the forecast period (2026-2031). This report is Segmented by Product Type (Instrument, Reagent, and More), Specimen (Serum/Plasma, Whole Blood and More), Assay Technique (ELISA, CLIA and More), Application (Anemia, Hemochromatosis, and More), End User (Hospitals, Diagnostic Laboratories and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Ferritin Testing Market Trends and Insights

Rising Prevalence of Iron-Deficiency Anemia

Iron deficiency anemia affects 1.2 billion people worldwide, with 28.6% prevalence among pregnant women in developing regions. The CDC’s 2024 data brief reported a 9.3% anemia prevalence among the U.S. population aged 2 and older, climbing to 22% in Black communities. These epidemiological burdens compel health systems to institutionalize routine ferritin testing for at-risk groups, supported by the WHO’s 2024 guideline that harmonizes hemoglobin cut-offs globally.Evidence shows ferritin below 30 ng/mL correlates with cognitive decline and reduced exercise tolerance, widening clinical justification for proactive screening. Standardized cut-offs and policy mandates directly feed continuous growth of the ferritin testing market.

Growing Burden of Chronic Kidney Disease (CKD)-Linked Anemia

CKD affects around 850 million people, and 40-60% develop anemia as renal function deteriorates. Hepcidin-mediated iron sequestration complicates management, making ferritin indispensable for differentiating absolute from functional deficiency ijms.com. Japanese practice audits revealed underuse of ferritin monitoring during therapy, flagging untapped market potential. Novel treatments such as ferric carboxymaltose and HIF stabilizers demand precise ferritin tracking to prevent iron overload. A 2024 study linked ferritin above 346.05 μg/L to higher mortality in hemodialysis patients, reinforcing its prognostic importance.

Availability of Alternative Transferrin Saturation Tests

Recent cardiology research shows transferrin saturation (TSAT) correlates more tightly with mortality risk in heart failure than ferritin. Guidelines now advocate TSAT below 20% as the iron-deficiency cut-off, especially in inflammatory states where ferritin may be falsely elevated. The American Heart Association’s 2024 statement encourages hypoferremia-based definitions, which could divert some testing volume away from ferritin. Nonetheless, ferritin remains indispensable in iron supplementation monitoring and in conditions absent of systemic inflammation, softening this restraint’s long-term force.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Government-Funded Maternal Health Screening Programs
• Adoption of POCT Ferritin Devices in Low-Resource Settings
• High Cost of Automated Immunoassay Analyzers

Segment Analysis

The reagents segment generated 50.78% of 2025 revenue and anchors the ferritin testing market through constant consumption by automated analyzers in core laboratories. Recent procurement cycles in reference hospitals demonstrate limited sensitivity to economic slowdowns, underscoring the stickiness of reagent demand. High-throughput CLIA platforms such as Roche cobas 8000 can process more than 400 tests per hour, which tightly couples reagent consumption to routine chemistry panels. In parallel, point-of-care devices are set to expand at a 8.85% CAGR, propelled by primary-care chains, emergency departments, and humanitarian clinics seeking rapid turnaround. BD’s fingertip collection tubes paired with Babson Diagnostics’ micro-sample processing hardware illustrate the pivot toward capillary-based workflows. The Preventis SmarTest Ferritin Home kit connected to a smartphone app shows how at-home testing broadens the ferritin testing market.

Industries supplying analyzers integrate middleware that automatically uploads results into electronic health records, simplifying coding for reimbursement. That feature has grown from a nice-to-have to a procurement requirement in North America and Europe. Manufacturers tie analyzer installations to reagent rental contracts, ensuring predictable sales over the device’s lifespan. On the POC side, bioMérieux’s 2025 acquisition of SpinChip Diagnostics signals that major in-vitro diagnostics firms will buy innovation rather than build it in-house. SpinChip’s centrifugal microfluidic platform delivers quantitative ferritin readings from whole blood within 10 minutes, narrowing the historical precision gap between lab-based CLIA and bedside tests. As accuracy converges, price transparency and ease of use will determine the pace at which POC devices erode the incumbent reagent-dominated revenue model.

Serum and plasma specimens contributed 67.10% of global revenue in 2025, reflecting long-established venipuncture workflows and their proven analytical robustness. Large hospitals prefer serum because high-speed centrifuges and automated track systems already exist to process thousands of samples daily. Yet whole blood testing is gaining traction at a 9.95% CAGR, buoyed by fingertip collection kits that reduce patient discomfort and eliminate centrifugation. Validation studies conducted by BD demonstrate quantitative agreement between capillary and venous draws within clinically acceptable limits, reinforcing clinician trust. Whole blood also aligns with humanitarian missions where cold-chain logistics remain a hurdle, making single-step assays attractive.

The ferritin testing market size for whole blood platforms is projected to broaden as centrifugal microfluidic cartridges achieve limits of detection below 15 ng/mL, adequate for pediatric anemia screening. Urine and saliva remain in early research stages. Pilot data show urinary ferritin tracks body iron stores in infants, though assay sensitivity must improve before commercial roll-out. Saliva-based lateral-flow cassettes under development at several U.S. universities aim to reach a detection threshold of 10 ng/mL, but present challenges in matrix effects and standardization. Long term, non-invasive matrices could unlock new patient cohorts, yet serum and whole blood are poised to remain mainstays through 2031.

Complete Report Scope:

• By Product Type
  • Instruments
  • Reagents
  • Kits
  • Point-of-Care Devices
  • Automated Analyzers
• By Specimen Type
  • Serum/Plasma
  • Whole Blood
  • Other Specimens
• By Assay Technique
  • ELISA
  • Chemiluminescence Immunoassay (CLIA)
  • Immunoturbidimetric Assay
  • Lateral Flow Assay
  • Others
• By Application
  • Anemia
  • Hemochromatosis
  • Lead Poisoning
  • Chronic Kidney Disease
  • Other Applications
• By End User
  • Hospitals
  • Diagnostic Laboratories
  • Clinics / POCT Centers
  • Research Institutions
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 30.95% of 2025 revenue, anchored by high awareness, comprehensive insurance coverage, and robust analyzer fleets inside acute-care hospitals. The U.S. Preventive Services Task Force’s 2024 update that formalized ferritin screening in pregnancy strengthened baseline demand. Canada’s provincial guidelines mirror the U.S. stance, while immigrant screening programs by the CDC add niche volume. Large commercial laboratories such as Quest Diagnostics benefit from cross-state logistics, reinforcing the region’s leadership.

Asia-Pacific is forecast to deliver an 8.62% CAGR, the highest globally, as governments institutionalize large-scale anemia control programs. India’s Anemia Mukt Bharat initiative funds digital reagent analyzers in district hospitals, creating a predictable pipeline for the ferritin testing market. China’s expansion of antenatal care under its two-child policy likewise broadens ferritin screening, while Japan’s nephrology societies issue new monitoring guidelines for CKD. Public-private partnerships accelerated point-of-care device trials in Indonesia and Vietnam, signaling fertile ground for mobile testing services.

Europe maintains steady adoption thanks to universal healthcare and the rollout of the In-Vitro Diagnostic Regulation, which harmonizes performance requirements. The ferritin testing market size in Europe remains anchored in hospital labs, but decentralized pilots in the United Kingdom’s NHS community hubs illustrate a gradual shift. Middle East and Africa are projected to expand but from a low base, constrained by infrastructure. Gulf Cooperation Council hospitals invest in automated immunoassay lines to align with JCI accreditation, while Sub-Saharan clinics rely on donor-funded lateral-flow strips. Latin America shows moderate growth, with Brazil incorporating ferritin in national prenatal protocols and Argentina piloting POC analyzers in primary-care outposts.

List of Companies Covered in this Report:

• Thermo Fisher Scientific
• Roche
• Siemens Healthineers
• Abbott Laboratories
• HORIBA
• bioMérieux
• Randox Laboratories
• DiaSys Diagnostic Systems
• QuidelOrtho
• Danaher
• Sysmex
• Abnova
• Aviva Systems Biology
• Eurolyser Diagnostica
• Monobind
• Sekisui Diagnostics
• Omega Diagnostics
• Mindray
• Bio-Rad Laboratories
• Euroimmun

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support